Opening book details…
Can I read Biomarkers of Alzheimer’s disease: Past, present and future clinical use on EtoBox?
Biomarkers of Alzheimer’s disease: Past, present and future clinical use by Joanna E. Georgakas; Matthew D. Howe; Louisa I. Thompson; Natalie M. Riera; Meghan C. Riddle is a Neuroscience article available to read on EtoBox.
What is Biomarkers of Alzheimer’s disease: Past, present and future clinical use about?
Alzheimer’s disease (AD) is an age-related neurodegenerative disease and the leading cause of dementia worldwide. AD is associated with several neuropathologic changes including the progressive accumulation of extracellular amyloid-β (Aβ) plaques, intracellular neurofibrillary tau tangles, neuroinflammation, cerebral small vessel disease and neurodegeneration, many of which are known to begin years before the onset of clinical symptoms. As such, there is a growing interest in developing biomarkers that can be used to detect these changes in the brains of at-risk individuals to facilitate earlier and more accurate diagnosis. This may allow for earlier intervention with disease-modifying therapies to slow the progression of irreversible neurodegeneration and improve quality of life. The current review seeks to provide a concise overview of the neuropathology and genetics underlying AD, and then summarize the most promising clinically available and experimental biomarkers of AD. These include structural neuroimaging, functional magnetic resonance imaging (fMRI), positron emission tomography (PET), cerebrospinal fluid (CSF), and blood-based assays. Multiple potential clinical uses for
Who reads Biomarkers of Alzheimer’s disease: Past, present and future clinical use?
It is typically read by researchers, students, and practitioners in Neuroscience.
- Author
- Joanna E. Georgakas; Matthew D. Howe; Louisa I. Thompson; Natalie M. Riera; Meghan C. Riddle
- Publisher
- Elsevier BV
- Published
- 2023
- Language
- EN
- Field
- Neuroscience (Life Sciences)